An Observational, Prospective Post-Marketing Surveillance Program to Evaluate theSafety Profile of Intravitreal Ozurdex® in the Treatment of Visual Impairment due to Diabetic Macular Edema by Actively Identifying and Evaluating the Occurrence of Adverse Events and Serious Adverse Events information

08/11/2016
02/07/2024
EU PAS number:
EUPAS16156
Study
Finalised
Documents
Study protocol
Initial protocol
English (155.56 KB - PDF) View document
Study results
Study results
English (117.31 KB - PDF) View document
Study report
Other information